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Abstract: In female mammals, mechanisms have been developed, throughout evolution, to integrate
environmental, nutritional and hormonal cues in order to guarantee reproduction in favorable
energetic conditions and to inhibit it in case of food scarcity. This metabolic strategy could be
an advantage in nutritionally poor environments, but nowadays is affecting women’s health. The
unlimited availability of nutrients, in association with reduced energy expenditure, leads to alterations
in many metabolic pathways and to impairments in the finely tuned inter-relation between energy
metabolism and reproduction, thereby affecting female fertility. Many energetic states could influence
female reproductive health being under- and over-weight, obesity and strenuous physical activity
are all conditions that alter the profiles of specific hormones, such as insulin and adipokines,
thus impairing women fertility. Furthermore, specific classes of nutrients might affect female
fertility by acting on particular signaling pathways. Dietary fatty acids, carbohydrates, proteins
and food-associated components (such as endocrine disruptors) have per se physiological activities
and their unbalanced intake, both in quantitative and qualitative terms, might impair metabolic
homeostasis and fertility in premenopausal women. Even though we are far from identifying a
“fertility diet”, lifestyle and dietary interventions might represent a promising and invaluable strategy
to manage infertility in premenopausal women.
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1. Introduction
Infertility, which is defined as not being able to conceive after one year of unprotected sex, is
an ongoing problem estimated to affect 186 million people worldwide [1]; in some regions of the
world, such as in developing countries, the percentage of infertility could reach an average of 30% [2].
Although male infertility contributes to more than half of all cases of global childlessness, infertility
remains a woman’s social burden [1]. The etiologies of female infertility include ovulation and tubal
problems, endometriosis and in 20%–30% cases remain unexplained [3]. Recently, the effects of lifestyle
on female reproductive health have received new attention [3–5]. Body weight, body composition,
physical activity, and nutrients intake are all factors that could impact female fertility [4].
In female animals, reproduction and metabolism are tightly connected and reciprocally
regulated [6,7]. During the reproductive period of life, the physiological activity of the gonads, with
their cyclic production of sex hormones, ensures continuous regulation of energy metabolism [6,7]. On
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the other hand, in females, in particular in mammals, energy metabolism is tuned on reproductive
needs: the energetic costs of puberty, pregnancy and lactation rely on female ability in saving oxidizable
fuels [6,8]. Throughout evolution mechanisms have been developed to store energy in the case
of food abundance and to prevent reproduction in nutrient poor environments [9,10]. When this
physiological balance between reproduction and metabolism is disrupted problems occur. Pathologies
associated with ovarian dysfunction, such as polycystic ovarian syndrome (PCOS) or Turner syndrome
are generally more susceptible to developing metabolic disturbances [11,12], and physiologically,
after the cessation of ovarian function, women are also at higher risk for developing metabolic and
cardiovascular disorders [13]. On the other hand, in our obesogenic world, the gender-specific strategy
developed throughout evolution to guarantee the survival of the species has negative effects on female
health [9] and is now also impacting women’s fertility [14].
Many studies reveal the J-shaped relation between body mass index (BMI) and infertility; indeed,
the effect of body mass on fecundity appeared to be bimodal. Underweight (BMI < 19 kg/m2) and
overweight (BMI 25–29.9 kg/m2) women have similar risk of infertility; on the other hand, morbidly
obese women (BMI > 30 kg/m2) have more than two fold greater risk of ovulatory disorders [4,5].
The impact of BMI on reproduction seems to be specific for females pointing, once again, to a sex
dimorphism in the mechanisms linking reproduction and metabolism. Indeed, being overweight
impairs fertility in women more than it does in men [15].
Given the tight interconnection between energy metabolism and reproduction, in this review, we
discuss the impact that the metabolic state, and related hormones (such as insulin and adipokines),
could have on fertility in women considering underweightness and exercise but also overweightness
and obesity. Moreover, we discuss the impact of different classes of macronutrients (fatty acids,
carbohydrates, and proteins) and of some food-associated components (endocrine disruptors) on
female health and fertility. Finally, we report the beneficial effects that Mediterranean diet was
suggested to have on women’s reproductive health.
2. Estrogen Receptor, the Link between Energy Metabolism and Reproduction
There is undoubtedly a tight interconnection between energy metabolism and fertility, above all
in females. This relation appears in less evolved animals, such as nematodes and insects: in these
species, indeed, signaling coming from metabolic organs senses energy reserves and in case of food
scarcity inhibits reproduction [6,16]. Recently, we reviewed the mechanisms that link female fertility
and energy metabolism throughout evolution, revealing that a central role in this regulation has been
gained by estrogens and their cognate receptors [6]. Estrogenic control over reproduction has long
been known and extensively studied. In the last years, their role in the control of energy metabolism is
also emerging [17,18]. Estrogen receptor alpha (ERα) is the one that mediates most of the estrogenic
effects on energy homeostasis: knock out mice for ERα, which are infertile, have increased body weight
and food intake when compared to their wild-type littermates [19].
In the central nervous system (CNS), particularly in the hypothalamus, which is the central
regulator of energy homeostasis, estrogens were demonstrated to decrease food intake, increase
energy expenditure and promote fat distribution to subcutaneous rather than visceral depots [20–22].
More in detail, estrogens regulate the expression of orexigenic neuropeptides, such as neuropeptide
Y (NPY) and agouti-related protein (AgRP), and the activity of anorexigenic neurons, such as
proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) [20–22].
Additionally, estrogens, acting both in the hypothalamus and in brainstem, potentiate the anorexigenic
signaling and attenuate the orexigenic ones produced by various peptides coming from the periphery,
such as cholecystokinin, leptin and ghrelin [23–25].
In the periphery, estrogens act at different levels. It is well documented that fertile-age women
have a subcutaneous instead of a visceral distribution of fat mass [18]. This effect seems to be dependent
upon estrogens activity: in post-menopausal women, when estrogenic signaling decreases, the
subcutaneous fat redistributes to the visceral area [18,26]. Additionally, estrogens were demonstrated
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to have an anti-lipogenic and pro-lipolytic activity in adipocytes [27,28]. Estrogens also promote
pancreatic β cells activity: they directly stimulate insulin biosynthesis and inhibit lipid accumulation
thus preventing lipotoxicity and promoting β cells survival [29–31]. In the liver, ERα, the main isoform
of the receptor in this tissue [32], has a relevant role in lipid homeostasis [33]. Studies conducted
in our and other laboratories demonstrated that hepatic ERα signalling regulates the expression of
many genes, the products of which are involved in fatty acid and cholesterol metabolism [33,34].
Additionally, we demonstrated that hepatic ERα is a sensor of the metabolic signals, and in particular
of amino acids, able to tune energy metabolism on reproductive needs [10].
3. Underweight and Exercise and Reproductive Outcome
When energy is scarce the mechanisms that partition energy favor the processes that ensure
the survival of the individuals over those promoting growth and reproduction [16]; this ancestral
mechanism is also true in women. Hassan and Killick showed that underweight women
(BMI < 19 kg/m2) have a four-fold longer time to pregnancy than women with a normal BMI.
Specifically, underweight women required an average of 29 months to conceive as compared to
6.8 months in women with a normal weight profile [5,35]. Indeed, as for the initiation of menses,
a minimum of fat mass is necessary, for maintaining ovulatory function [36]. Conditions of energy
deficit, such as eating disorders (ED), malnutrition and strenuous physical activity, are associated with
subfecundity and infertility [36–38].
Undernutrition due to low food availability is not common in developed countries but, in poorer
ones, is certainly connected with infertility risk [36]. In developed nations, conditions that produce
malnutrition are eating disorders (ED), a spectrum of psychiatric disturbances that affects childbearing
age women [39]. EDs are associated with hypothalamic amenorrhea, oligomenorrhea, anovulatory
cycles, and luteal phase deficiency [31,37]. At the level of the CNS, food deprivation was demonstrated
to inhibit the hypothalamic-pituitary-gonads axis (HPG), affecting GnRH pulse generator. Inhibition
of GnRH secretion leads to a cascade of inhibitory effects, including decreased gonadotropin secretion,
retarded follicle development, and inhibited synthesis of gonadal steroids [16,40–42].
Nutritional signals coming from the periphery are also important for the regulation of
reproduction. Studies conducted in our laboratory showed that hepatic ERα is an important mediator
of these effects [10]. Calorie restriction induces a decrease in liver ERα activity, which is associated with
a disruption of the estrous cycle, whereas dietary amino acids (AAs) prevent this effect by promoting
hepatic ERα activity, inducing liver IGF-1 synthesis and enabling estrous cycle progression [10].
Physical activity (PA) is also associated with menarche and reproductive health [43]. Frequency,
duration and intensity of PA are all correlated with subfecundity and infertility [38]. Precisely, moderate
exercise and weight loss improve metabolic function and hormonal profile in obese women, often
leading to increase fertility [44,45]. On the other hand, women that exercise to exhaustion have
2.3–3 fold increased risk of infertility [38]. While, for a long time, it was believed that ovarian
disturbances in athletes could be dependent on fat mass, it is now appearing clear that physical
activity effects on reproduction are independent of body fat stores [46]. Menstrual cycle returns in
female athletes when energy expenditure is reduced even without changes in body weight and fat
mass [46,47]. It is plausible that is the negative energy balance due to high loads of exercise not coupled
with increased energy intake, which leads to menstrual cycle disruption [46,48].
4. Obesity and Fertility
The global obesity epidemic is now pandemic [49]. In 2009–2010, the prevalence of obesity in the
United States was 35.5% among adult men and 35.8% among adult women [50]; in 2011–2012, 32.2% of
children in the US aged 2 to 19 years were overweight and 17.3% were obese [51]. Obesity is associated
with the development of type 2 diabetes mellitus, coronary heart disease, certain forms of cancer and
multiple alteration of the endocrine system, such as PCOS [52–54].
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Childhood BMI is correlated to pubertal development: greater adiposity was reported to induce
menarche at earlier age [55]. This predisposes women to higher risk of obesity, diabetes and breast
cancer [55–57]. Additionally, obesity clearly increases women’s risk of fertility impairment, in
particular menstrual disorders, infertility, miscarriage, poor pregnancy outcomes, and impaired
fetal well-being [14,58,59]. This topic is appealing and alarming, as demonstrated by the increased
number of publications appeared in the last 35 years (Figure 1). In ovulatory but subfertile women the
chance of spontaneous conception decreases by 5% for each unit increase in the BMI (body mass index)
exceeding 29 kg/m2 [5,60]. Overweightness and obesity are also associated with negative outcomes
for patients undergoing in vitro fertilization [14,61]. Indeed, the increased risk of subfecundity and
infertility in overweight and obese women is associated with not only impairment at the level of
the HPG axis, but also oocyte quality and uterine receptivity [61,62]. Given this, it is recommend
overweight and obese women lose weight in order to improve fertility [5]. Overweightness effects on
fertility seem to be sexually dimorphic. In a study conducted in 483 men, it was observed that BMI
was unrelated to sperm concentration, motility and morphology [15]. Only in obese subjects, the total
sperm count was lower in comparison to normal weight men [15].
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Figure 1. Number of publications reporting the association between  female  infertility and obesity. 
The great increase in number of reports appeared per year since 1980 reveals that the interest in the 
topic has increased during the last decades. Data were obtained using WOS (Web of Science). 
Dyslipidemia  is often observed  in obese patients, with  increased plasmatic  triglycerides and 
free  fatty acids, decreased HDL‐C  (high‐density  lipoprotein cholesterol) and slightly  increased  in 
LDL‐C (low‐density lipoprotein cholesterol) [63]. There is a body of literature pointing out the role of 
lipids  for  female  fecundity;  indeed,  cholesterol  and  fatty  acids  are determinant  for  reproductive 
function  at  the  level  of  ovary,  uterus  and  placenta  [64–66].  Recently,  serum  free  cholesterol 
concentrations,  in  both women  and men,  have  been  associated with  reduced  fecundity  [67]. An 
abnormal  lipoprotein metabolism  has  been  correlated  to  dysfunctional  oocyte  and  infertility,  as 
observed in SR‐BI (scavenger receptor BI) gene knock out mice [68]. Using this model, the authors 
clearly showed the existence of a hepatic‐ovarian axis necessary for female reproductive function. 
This  mechanism  has  never  been  extensively  studied  although  it  could  be  a  key  in  linking 
reproduction with metabolism. A recent work performed in our laboratory revealed that, in female 
mice, the estrous cycle coordinates cholesterol homeostasis and that hepatic ERα is necessary for this 
effect [69]. Altogether, these data further highlight that the influence of metabolism on reproduction 
is bidirectional. 
Finally, insulin resistance is often correlated with obesity; the effect of this pancreatic hormone 
on female fertility has been extensively studied and is reviewed in the next section. 
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Figure 1. f blications reporting the association between female infertility and obesity. The
gr at increase in number of reports appeared p r year since 1980 reveals that t e int rest in the topic
has increased during the last decades. Data were obtained using WOS (Web of Science).
Dyslipide ia is often observed in obese patients, with increased plasmatic triglycerides and free
fatty acids, decreased HDL-C (high-density lipoprotein cholesterol) and slightly increased in LDL-C
(low-density lipoprotein cholesterol) [63]. There is a body of literature pointing out the role of lipids
for female fecundity; indeed, cholesterol and fatty acids are determinant for reproductive function
at the level of ovary, uterus and placenta [64–66]. Recently, serum free cholesterol concentrations, in
both women and men, have been associated with reduced fecundity [67]. An abnormal lipoprotein
metabolism has been correlated to dysfunctional oocyte and infertility, as observed in SR-BI (scavenger
receptor BI) gene knock out mice [68]. Using this model, the authors clearly showed the existence of
a hepatic-ovarian axis necessary for female reproductive function. This mechanism has never been
extensively studied although it could be a key in linking reproduction with metabolism. A recent work
performed in our laboratory revealed that, in female mice, the estrous cycle coordinates cholesterol
homeostasis and that hepatic ERα is necessary for this effect [69]. Altogether, these data further
highlight that the influence of metabolism on reproduction is bidirectional.
Finally, insulin resistance is often correlated with obesity; the effect of this pancreatic hormone on
female fertility has been extensively studied and is reviewed in the next section.
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5. Insulin and Adipokines: The Most Involved Molecular Players Linking Obesity and
Reproductive Impairment
From what is said above, it appears clear that energy metabolism and female fertility are tightly
connected and reciprocally regulated. Not surprisingly many peripheral signals report nutritional
status to the CNS and to the ovary in order to coordinate reproduction. Undoubtedly, hormones
derived from the gut, adipose tissue and pancreas (such as peptide YY, adipokines, insulin and others)
were recognized as regulating human reproduction, as these tissues are ideally placed to sense and
detect nutritional intake and status [70,71]. In the sections below, we decided to focus our discussion
on the signal of insulin and adipokines as they are largely described to mediate the negative impact
that obesity has on fertility, highlighting their effects at the level of the HPG axis and their influence on
steroidogenesis, as summarized in Figure 2.
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Figure  2.  Effects  of  insulin,  leptin  and  adiponectin  on  the  regulation  of  hypothalamic  pituitary 
gonadal  axis  (HPG)  and  steroidogenesis  under  physiological  and  obesity‐associated  conditions. 
Under physiological conditions (left) the signaling pathways of insulin, leptin and adiponectin are 
able  to  sense  the  nutritional  status,  and,  jointly with  sex  hormones  sustain  ovarian  activity  and 
reproduction. In obesity (right), the increased levels of insulin and leptin lead to insulin and leptin 
resistance that, together with the reduced adiponectin levels, contribute to a dysregulation of both 
the HPG axis and ovarian steroidogenesis, by further worsening the endocrine milieu (impaired E2 
and  P4  synthesis,  increased  T  synthesis  and  free  levels  due  to  reduced  SHBG  synthesis)  and 
impairing ovarian function and fertility success rate. In the figure the dotted lines represent impaired 
regulations. E2 = 17β‐estradiol; P4 = progesterone; T = testosterone. 
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in  response  to  increased  blood  glucose  levels,  insulin  stimulates  glucose  uptake  by  the  skeletal 
muscle and by the adipose tissue and regulates lipid metabolism in the liver. 
Insulin resistance (IR) is a disorder characterized by an impaired metabolic response to either 
exogenous or endogenous  insulin, with consequences on carbohydrate,  lipid and protein metabolism 
[73]. Pancreatic  β cells  try  to counteract  insulin  resistance by enhancing  their mass and secretory 
activity;  however,  when  the  functional  expansion  of  islet  β‐cells  fails  to  compensate,  insulin 
deficiency and ultimately type 2 diabetes (T2D) develop [74]. IR and T2D are highly correlated with 
lifestyle, in particular with overweightness and obesity. T2D incidence is approximately 90% lower 
in middle‐age women with a normal weight, who exercise regularly and eat a diet rich in cereal fiber 
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independent of obesity, strongly correlates with PCOS, a common endocrinology disorders that is 
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deficiency and ultimately type 2 diabetes (T2D) develop [74]. IR and T2D are highly correlated with
lifestyle, in particular with overweightness and obesity. T2D incidence is approximately 90% lower in
middle-age women with a normal weight, who exercise regularly and eat a diet rich in cereal fiber and
in poly-unsaturated fats and poor in saturated and trans fats [75]. Insulin resistance, independent of
obesity, strongly correlates with PCOS, a common endocrinology disorders that is estimated to affect
between 5% and 10% of reproductive age women [76,77]. This pathology is often characterized by some
aberrations in the secretion of gonadotropins and, in particular, with high levels of LH (luteinizing
hormone) [78]. Moreover, insulin, through its own receptor, has been demonstrated to have direct effect
on steroidogenesis in the ovaries [79]. In vitro studies using theca cells from mammalian ovaries have
shown that insulin has dose-dependent effects on cell proliferation, steroid production, and expression
of genes, such as STAR (steroidogenic acute regulatory protein), CYP11A1 (cytochrome P450 family
11 subfamily A member 1), and CYP17A1 (cytochrome P450 family 17 subfamily A member 1), overall
promoting steroidogenesis [80–83]. In normal, theca cells, insulin, in synergy with LH stimulates
CYP17A1 gene expression and the 17α-hydroxylase activity of its product [84], a key enzyme in
the regulation of androgen biosynthesis [85], but the molecular mechanism involved in this effect
have not been completely elucidated and many conflicting results exist [84,86]. Under physiological
conditions, insulin acts as a co-gonadotrophin in theca cells; on the other hand, hyperinsulinemia
potentiates gonadotropin-stimulated ovarian androgen synthesis [87,88]. Additionally, in PCOS
there is selective insulin resistance on the ovary, as reported for other tissues: insulin action on
steroidogenesis is preserved, while insulin action on glucose metabolism is significantly decreased
in granulosa-lutein cells from classical PCOS patients [89]. Furthermore, insulin inhibits the hepatic
synthesis of sex hormone-binding globulin (SHBG), thus increasing free testosterone levels [87]. All
the treatments aimed at reducing insulin levels, such as weight loss and insulin sensitizers, improve
female reproductive health.
On the other hand, type 1 diabetes (T1D) is a condition in which pancreatic β-cells destruction
leads to absolute insulin deficiency [90]. Hypogonadotropic hypogonadism is present in women
with uncontrolled type 1 diabetes [91] and, despite a significant improvement in the therapy for T1D,
patients still experience abnormalities in pubertal development, menstrual cycle and menopause
age [92]. Experimental evidence further supported the clinical data showing that insulin plays
an important role in the regulation of female fertility. Animal models characterized by severe
insulinopenia, which mimic T1D, were obtained by treatment with streptozotocin (STZ); indeed,
STZ causes rapid and selective elimination of pancreatic β cells [93]. Both STZ males and females
exhibit a hypogonadotropic state, characterized by low levels of gonadotropins and sex steroids and
by reduced LH pulsatility [94–96]. Central insulin administration in STZ treated rats induce normal
LH surge, despite the maintenance of peripheral diabetes revealing that insulin action on reproduction
occurs at multiple levels [97]. Indeed, insulin receptors (IRs) are located in the CNS in many areas
involved in the control of reproduction such as the arcuate, the ventromedial hypothalamic nucleus
and the preoptic area [98,99]. Additionally, genetically engineered mice, with a specific deletion of
insulin receptor in the CNS, display hypogonadotropic hypogonadism [99]. It appears thus clear that
insulin has a great impact of female fertility acting both centrally and in the periphery.
5.2. Adipokines
Adipose tissue participates in the regulation of energy homeostasis by acting as an endocrine
organ. Indeed, it produces a series of adipokines, which comprises leptin, adiponectin, resistin, tumor
necrosis factor-α, interleukin-6, apelin, vaspin, visfatin, hepcidine, chemerin, omentin and many
others [100–102]. Many of these factors interact with the signal of insulin and could thus indirectly
affect reproduction [101]. For others, a clear and direct mechanism affecting fertility has been described;
in particular, many studies focused on adiponectin and leptin.
Adiponectin concentration correlates negatively with visceral fat mass in mammals: higher
plasmatic concentrations are usually detected in women as compared to men [103] and low levels are
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generally observed in obese patients [104]. Adiponectin exerts insulin-sensitizing, anti-atherosclerosis
and anti-inflammatory actions [105–107]; indeed, adiponectin participates in many metabolic processes
by modulating insulin sensitivity as well as glucose and lipid metabolism [108]. It seems to have
insulin-like effects on target tissues and it was demonstrated to play a role in the regulation of female
reproductive functions [101]; indeed, mammalian ovary, uterus and placenta express adiponectin
receptor (AdipoR1 and R2) [101,109]. In vitro and in vivo studies support this view, showing that,
in the ovary, adiponectin stimulates steroidogenesis by granulosa cells [109,110] and may play a
role in pre-implantation embryo development and uterine receptivity [107]. Adiponectin effect on
reproduction could be, at least in part, mediated by its action in the CNS: adiponectin mRNA and
AdipoR1 and R2 are highly present in human pituitary [111], where studies conducted in cycling pigs
demonstrated that receptors levels vary in response to estrous cycle progression [112,113]. In particular,
adiponectin was demonstrated to decrease, in pituitary cell culture, GnRH receptor mRNA and LH
release [114]; at this level, adiponectin has been proposed to be involved in an autocrine/paracrine
control of pituitary gonadotrophs [112]. Finally, polymorphisms in the human adiponectin precursor
gene have been associated with pre-eclampsia and PCOS, and low concentrations of this hormone
were found in PCOS patients [101,115–117]. Thus, as adiponectin receptors are present and active in
many reproductive tissues and given the low levels of the hormone in obese patients, adiponectin
could represent an important link between the reproductive system and the adipose tissue [118].
Leptin is produced by the adipose tissue in proportion to the amount of triglycerides stored [119].
Circulating levels of this hormone in humans are highly correlated to BMI and increased markedly in
obese subjects [120]. Under physiological conditions, leptin functions to maintain energy homeostasis
by reducing food intake, regulating pancreatic islet cells, and fat stores; in obese subjects leptin
resistance results in a dysfunctional energetic state [102]. Leptin plasmatic concentrations show sexual
dimorphism due, at least in part, to the fact that estrogens promote while androgens suppress leptin
synthesis [121,122]. This hormone has been proposed to play a role in the neuroendocrine adaptation
to starvation [123]. Low leptin serum concentrations were observed in amenorrheic athletes and
in women with anorexia nervosa and could, at least in part, explain the hypothalamic amenorrhea
affecting those patients [124]. Indeed, leptin exerts its effects on reproduction acting at multiple
sites [125]. In the hypothalamus, it facilitates GnRH secretions through indirect mechanism [126].
Leptin deficient female mice are infertile with low levels of gonadotropins and sex steroids [127,128]
and leptin treatment, but not weight loss, corrects sterility [129]. Additionally, individuals with
rare leptin deficiency or leptin receptor mutations have hypogonadotropic hypogonadism [128], and
leptin administration improves ovarian function in women with hypothalamic amenorrhea [128,130].
Leptin also has a role in ovary and follicular development: in particular, high concentrations of this
hormone, such as those observed in obese patients, interfere with estradiol production and oocyte
maturation [131]. Leptin receptors have been identified in granulosa, theca and interstitial cells of
human ovary, and leptin itself is expressed in human and rat ovaries, where its levels fluctuate
across the estrous cycle [132–134]. Several in vitro and in vivo studies demonstrated that the treatment
with medium-high physiological doses of this hormone, to resemble those observed in obese patients,
inhibited steroidogenesis in human granulosa and theca cells leading to a marked decline in the number
of ovulated oocytes [135–137]; on the other hand, another study shows that leptin treatment impairs
the ovulatory process without affecting steroid levels [138]. Studies on leptin levels in PCOS patients
lead to contradictory results. Several investigations reported an increased leptin concentration in PCOS
and hypothesized a direct involvement of this hormone in the etiology of the pathology [139–146].
Others find no differences in leptin levels between subjects with or without PCOS [147–153]: this
incongruity could be due to sample sizes, type of sample collection and the heterogeneous nature of
the pathology.
In conclusion, it has been hypothesized that very low leptin concentration, as a signal of energy
insufficiency, would suppress the reproductive function at the HPG level, while elevated leptin levels,
such as those observed in obesity, may have direct inhibitory effects on the gonads.
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5.3. AMPK, a Molecule Mediating the Signalling of Insulin and Adipokines
Many of the metabolic effects induced by the signals discussed above are mediated by an
important molecular player: AMP-activated protein kinase (AMPK). AMPK is a serine/threonine
heterotrimeric kinase, sensitive to the AMP: ATP ratio, activated by an increasing AMP concentration
and by the upstream kinases including liver kinase B1 (LKB1) and calcium/calmodulin kinase
(CaMKK) [154,155]. AMPK is activated in pathophysiological situations (exercise, stress), by metabolic
hormones (leptin and adiponectin) or by pharmacological and natural agents (such as metformin,
resveratrol and berberine) [156]. It functions as an intracellular energy sensor that switches off
ATP-consuming pathways (anabolic, such as protein, glycogen and sterol synthesis) and switches on
ATP-producing pathways, such as glycolysis, glucose uptake, mitochondrial biogenesis and fatty acid
oxidation [157,158]. The AMPK pathway was viewed primarily as a sensor and regulator of energy
balance at cellular level; however, in mammals, it has been demonstrated to be involved in the whole
body regulation of energy metabolism responding to both nutritional and hormonal signals in the
CNS as well as peripherally [159]. In the central nervous system, hypothalamic AMPK plays a critical
role in hormonal and nutrient-derived anorexigenic and orexigenic signals and in energy balance:
dominant negative AMPK expression in the hypothalamus is sufficient to reduce food intake and
body weight, whereas constitutively active AMPK increases both of them [160]. In the hypothalamus,
AMPK mediates the signaling of leptin, insulin and adiponectin. Indeed, in contrast to the periphery,
the anorexigenic hormone, leptin, and also insulin inhibit hypothalamic AMPK activity, thus reducing
food intake [160–162]. On the other hand, the opposite effect has been observed with adiponectin [163]:
adiponectin-KO mice showed decreased AMPK activity in the arcuate, decreased food intake, and
increased energy expenditure, exhibiting resistance to high-fat-induced obesity [163].
AMPK is ubiquitously expressed and plays a central role in peripheral organs metabolism such
as skeletal muscle, liver and fat, integrating the signaling of leptin, insulin and adiponectin [164–166].
In skeletal muscle, leptin causes a rapid activation of AMPK thus promoting fatty acid oxidation and
energy expenditure [167], the same effect has been observed also in the liver: leptin or leptin-receptor
knock out mice showed a reduced AMPK hepatic activity [168]. Adiponectin, through the binding to
its receptors, stimulates processes that provoke an increase in AMP and mice treated with adiponectin
have enhanced AMPK activation in both skeletal muscle and liver [169,170], thus promoting fatty acid
oxidation, glucose uptake and inhibiting glucose production [169,170].
AMPK certainly has a relevant role in the regulation of reproductive function: centrally, its
activation by adiponectin has been demonstrated to participate in the regulation of GnRH and LH
secretion in response to energy status, in hypothalamic and pituitary cell lines. Several studies have
also demonstrated that AMPK is expressed in the gonads [171–173] and could play a key role in
linking reproductive function with energy balance. Indeed, AMPK is present in granulosa and theca
cells, oocytes and corpora lutea in different species: birds [174,175], mammals [171,176–178] and
humans [179]. AMPK was demonstrated to participate in the control of gonad steroidogenesis and
germinal cell maturation but also cell proliferation and survival, polarity, formation, and maintenance
of cellular junctional complexes, and cytoskeletal dynamics [180]. Even if no studies have shown a
role of AMPK in ovarian steroidogenesis in vivo, this has been largely demonstrated in vitro. AMPK
activators, such as metformin, inhibit the secretion of progesterone and/or estradiol by granulosa cells
in mammals [171,176]. In rats, AMPK activation induced by metformin does not reduce aromatase
expression and estradiol production but it decreases progesterone synthesis and the expression of
different proteins involved in steroidogenesis [181]. In human granulosa cells, metformin also decreases
androgen synthesis, by directly inhibiting CYP17A1 activity [182].
6. Nutrients as Signaling Molecules
The ability to sense nutrients and to adapt physiological responses to nutrient availability and
characteristics allowed organisms to increase their opportunities to survive and to expand their
progenies: in one word, to evolve. This ability became relevant for female mammals, in particular
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with placenta advent: energy metabolism and fertility started to be tightly connected and reciprocally
regulated to adapt energy production and storage to the requirements of reproduction [6]. It appears
thus clear that nutrients cannot be merely considered a source of energy but they exert a bioactive role;
indeed, nutrients represent the main signals for organisms, which behavior cannot disregard from the
environment because they must take advantage of the available nutritional resources. According to this
view, an increasing amount of literature demonstrates the relevance of the food-dependent modulation
of nuclear receptors activity, which has been established and improved throughout evolution.
Nutrients ability in modulating the activity of nuclear receptors mainly occurs through the
regulation of signal transduction of the respective regulated pathways. For example, it is well known
that fatty acids are the natural inducers of PPARs (peroxisome proliferator-activated receptors alpha,
beta, and gamma), nuclear receptors that regulate the transcription of genes involved in cellular
differentiation, development, metabolism, and tumorigenesis [183–186]. Like fatty acids for PPARs,
other classes of nutrients may act as agonists of other transcription factors, such as glucose for liver
X receptor alpha (LXRα) [187] or amino acids for ERα [6]. Furthermore, some pathways are greatly
inter-connected, as demonstrated by different studies highlighting the relevance of the cross-talk
between LXRα and PPARα for the modulation of hepatic lipogenesis [188] or between LXRα and
farnesoid X receptor (FXR), which regulates bile acids, sterols and fatty acids, which, in turn, are the
activators of FXR, LXRα and PPARα, respectively [189]. All these nuclear receptors have a pivotal
role for female fertility [190–196], thus supporting the possibility that specific class of nutrients may
contribute to the coordination of energy metabolism and fertility acting as signaling molecules on
these receptors.
6.1. Poly-Unsaturated Fatty Acids and Female Fertility
In women, the reproductive process and its success are affected by the trend in postponing
childbearing, typical in the Western societies [197]. In fact, over the past century, the reproductive
lifespan of women has not proportionally increased with the increased woman’s life expectancy [198],
as women fertility precipitously declines after the age of 35 [199]. The discrepancy between the overall
and the reproductive lifespan of women is more pronounced today than ever before and could be
partially related to the changes in the human diet over the past 100 years, most notably with regard to
the type and amount of fat consumed [200,201].
In Western diets, the daily caloric intake of fatty acids was estimated around 30%–35%, a value
that far exceeds the nutritional requirements [202,203]. Some specific classes of fatty acids, such as the
poly-unsaturated (PUFA) omega-3 (n-3) and omega-6 (n-6) fats, need to be provided with the diet, as
they are indispensable for different biological processes, including growth, brain development and
reproduction and animals are not able to synthesize them [204–206]. Different studies highlighted
the beneficial effects exerted by PUFA on metabolic parameters when compared to other type of
fatty acids, in particular trans fatty acids (TFA) and saturated fatty acids (SFA), and to a lesser extent
mono-unsaturated fatty acids (MUFA) [207–211]. However, the beneficial effects exerted by PUFA in
counteracting metabolic diseases could be influenced by the type of PUFA, as the optimal n-6:n-3 PUFA
ratio changes depending on the pathophysiological condition [212]. Furthermore, other studies have
downsized the beneficial metabolic effects of PUFA over other type of fats, in particular MUFA [213].
In women, consumption of TFA instead of MUFA or PUFA is positively associated with ovulatory
infertility, independent of age, BMI, lifestyle and hormonal levels [4]. At the mechanistic level, it
has been proposed that the detrimental effects of TFA on fertility could be due to their different
ability to bind PPARγ and down-regulate its expression [214–216]. Furthermore, the higher intake
of TFA has been associated with altered metabolic parameters, such as insulin resistance [217], risk
of T2D [218], and inflammatory markers [219,220], which may negatively impair ovarian functions.
Replacing TFA with MUFA has been demonstrated to be associated with a lower risk of ovulatory
infertility [4], although these conclusions could be only partially ascribable to the changes in dietary
fats and could be further affected by other nutritional factors, such as the source of proteins (vegetable
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vs. animal), the higher intake of high-fiber, low glycemic carbohydrates, high-fat dairy products, and
other micronutrients [4].
In addition, several studies demonstrated that a higher intake of PUFA [221–224] instead of
TFA [225], SFA [225] or MUFA [226] has been associated with the improvement of metabolic and
hormonal characteristics in women with PCOS [221]. However, other studies performed in PCOS
women failed to confirm some of these beneficial effects [221] and have found that a diet enriched in
MUFA instead of PUFA could be more useful in ameliorating the metabolic profile and consequently
the fertility rate [227].
The relative n-6 and n-3 PUFA content has been significantly changed: in the Western diet, the ratio
of n-6 to n-3 PUFA ranges from 10:1 to 25:1, greatly diverging from the 1:1 ratio typical of the primitive
diet, from which our genetic constitution was selected. This change in diet composition, over the last
100 years, has been associated to decreased fertility rates in women over the age of 35 [228]. At the
mechanistic level, the proportion of different PUFAs in the diet significantly influences prostaglandin
(PG) [229–231] synthesis and ovarian steroidogenesis, both having crucial role in the reproductive
process [232,233].
PUFA, in particular arachidonic acid (AA) and its metabolites, influence steroidogenesis in female
mammals by exerting direct effects on specific enzymes such as STAR and CYP11A1, and on the
regulation of PG synthesis [229]. PUFA may also alter the function of nuclear receptors such as
LXRα [234] and PPARs [230], by influencing the transcription of their target genes involved in PG
synthesis and ovarian steroidogenesis [235]. Furthermore, the amount and type of dietary PUFA might
affect several metabolic pathways and the consequent metabolic impairment might cause negative
reproductive outcomes [236]. The amount and the type of dietary PUFA might affect different stages
of the reproduction, not only ovarian steroid synthesis [237], but also oocyte maturation [238], uterine
activity [239], pregnancy [240] and labor [241].
The association between the increased n-6:n-3 PUFA ratio in Western diet and the reduced fertility
lifespan in women suggests that a diet enriched in n-3 PUFA could be useful in counteracting the
relative excess of n-6 PUFA and could thus improve the reproductive success. Although some
studies seem to confirm this hypothesis [242–244], other works do not sustain any positive effect
of PUFA on female reproduction [245,246] or even report health problems associated to chronic
treatments [241]. This discrepancy could rely on the fact that some investigations were underpowered,
lack appropriate controls or were directed only on a specific subset of PUFA [240]. In addition, the
specific mechanisms underpinning the positive impact of n-3 PUFA on the female reproductive axis
remain to be fully elucidated.
In female mammals, diets enriched in n-3 PUFA enhance plasmatic levels of 17β-estradiol
(E2) [232,247,248], thereby leading to increased secretion of GnRH and triggering the LH surge. The
mechanism behind the enhanced E2 synthesis is still unclear; however, several explanations have
been suggested: PUFA supplementation might enhance plasma steroid concentrations by increasing
the availability of lipoprotein–cholesterol, by modulating PG synthesis, or by directly stimulating
ovarian steroidogenesis [249,250]. Conversely, other studies [251,252] suggested that the greater and
long-lasting elevation of E2 levels in female mammals consuming n-3 PUFA could be due to the
inhibitory effects exerted by n-3 PUFA on the metabolism of steroid hormones in the liver [253–255].
The delay in E2 surge and in the consequent positive feedback of E2 on hypothalamus and
pituitary could explain the tendency for a delay in LH peak and ovulation observed in females
supplemented with PUFA [256]. Furthermore, dietary PUFA could influence ovulation timing by
acting on PG synthesis and PG-mediated changes in LHRH release [257,258].
Some studies showed that the content of E2 and the 17β-estradiol/progesterone (E2/P4) ratio,
a reliable indicator of follicles health [259,260], are increased in the pre-ovulatory follicles of females
supplemented with PUFA [261]. All these hormonal changes contribute to the increased number and
size of pre-ovulatory follicles and may be beneficial for ovarian function.
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In PCOS women, the supplementation of n-3 PUFA ameliorates both the metabolic and hormonal
parameters (in particular, by decreasing the levels of androgens) [223,226], even if others studies failed
to unravel significant changes in the regulation of HPG axis [221]. Conversely, studies done in a
rat model of PCOS demonstrated that dietary n-3 PUFA are able to increase the mean of FSH and
significantly decrease the testosterone levels [262].
6.2. Carbohydrates and Sugars and Female Fertility
The strong relationship between decreased insulin sensitivity and women infertility observed
in diabetics and PCOS women [263] suggests that the amount and quality of carbohydrates in diet
might influence reproductive functions. The existence and the mechanism of the correlation between
sugars and reproduction, in healthy premenopausal women, are far from being fully elucidated: in the
literature, many conflicting data are present.
On the one hand, some studies demonstrated that the quality of quantity of dietary carbohydrates
might be associated with ovulatory infertility among nulliparous women [264]. The mechanism
could be mainly ascribable to reduced insulin sensitivity that leads to increased free IGF-I and
androgen levels [265], thus reproducing some clinical features typical of PCOS [78]. The impact
of carbohydrates on the HPG axis has been suggested in a longitudinal study done in women, where a
low-fat, high-carbohydrate diet decreased significantly the blood levels of E2 and P4 and increased
the levels of FSH and the ratio FSH:E2, independent of age and weight [266]. The lower E2 levels and
the longer menstrual cycles observed in women subjected to this diet partly reflect the changes in the
years that precede the menopause [267]. On the other hand other studies did not found any significant
association between dietary intake of these macronutrients and plasma sex steroid levels [268,269].
These discrepancies could rely on the different protocol adopted (intake and sources of carbohydrates,
length of the treatment) and on the magnitude of the study. The main effects of high intake of
carbohydrates could be mainly mediated by insulin and its signalling pathway, thereby affecting
the HPG axis (see also Section 5.1). A captivating explanation suggests that the impairment of the
ovulatory process is not due to the increased carbohydrate intake per se, but could rather be linked to
the fact that the increasing carbohydrate intake is at the expense of natural fats, which exert a beneficial
effect on ovulatory function [270].
Even if the consumption of carbohydrates and sugars—particularly fructose in liquids, such
as in sugar-sweetened beverage (SSB)—is decreasing [271], mean intakes among premenopausal
women continue to exceed recommendations and might affect the reproductive process. Diets high
in carbohydrates/sugars lead to dyslipidemia and insulin resistance, thereby causing hormonal
and ovulatory disorders, however very few studies have assessed the effects of energy containing
beverages on hormonal levels and ovulatory function in premenopausal women. One study showed
that high carbohydrate intake is associated with an increased risk of anovulatory infertility: dietary
glycemic index is positively related to this condition in a cohort of apparently healthy women [264].
However, other studies did not found any association between SSB and premenopausal reproductive
hormones [272,273] or, even if they showed an association between sugars intake and elevated follicular
free and total estradiol, these altered hormone levels do not interfere with ovulation among healthy
premenopausal women without ovulatory disorders [274,275].
This discrepancy might, once again, be due to limitations in the studies, such as small sample
sizes and/or inadequate assessment of nutritional and hormonal variables.
6.3. Proteins, Amino Acids and Female Reproduction
Few studies done in overweight women with PCOS [276,277] showed that diet enriched in
proteins (30% vs. 15% of total energy) improved menstrual cyclicity by reducing circulating androgens
levels and improving insulin sensitivity as a consequence of weight loss. In these studies, the increased
protein intake had no effect on reproductive function per se indeed, the small improvements in
Nutrients 2016, 8, 87 12 of 34
menstrual cyclicity seems to be ascribable to a greater insulin sensitivity associated to a reduced
carbohydrates intake (replaced by proteins) rather than an increased dietary protein intake.
The Nurses’ Health Study II (NHS II) highlighted the association between animal proteins
intake and increased risk of ovulatory infertility in a cohort of healthy women [278]; conversely, the
consumption of proteins from vegetable sources instead of carbohydrates or animal protein was
associated with a substantially lower risk of ovulatory infertility, at least among women older than
32 years [278], thus suggesting that protein intake may differently affect female fertility depending
on the protein source. Although the biological mechanisms responsible for this association have not
been identified, evidence indicates that the benefits associated to a diet enriched in proteins from
vegetable instead of animal sources might rely on the increased insulin sensitivity [279,280] and might
be associated to changes in circulating free IGF-I levels [281].
These evidences seem to contradict other studies showing an association between
vegetarian/vegan diets and menstrual disturbances [282–287]. However, most of the studies showing
a correlation between these diets and menstrual disturbances were performed in athletes, in which
the elevated energy expenditure consequent to physical activity may be the main cause leading to
reproductive alterations. Similarly, the menstrual disturbances observed in vegetarian women, who
are generally leaner and lighter than non-vegetarian ones [288–290], may be due to reduced energy
availability and increased physical activity [290] rather than a deficiency in dietary protein intake.
The reproductive effects of vegetarian/vegan diets have not been fully elucidated. Very few
studies showed impairments in the reproductive parameters among vegetarian women in comparison
to non-vegetarians [285]. Others did not support any vegetarian diet dependent difference related
to the reproductive process [291]. Similarly, although some studies showed altered reproductive
outcomes [292–296], others did not support any significant differences between vegetarian and
non-vegetarian diet in relation to pregnancy outcomes [297–299]. These discrepancies may be due to
the paucity and limitations of the studies; indeed, they often did not take into account the possible
effects dependent upon changes in others macronutrient classes such as fat and fiber and the lifestyle
of vegetarian vs. non-vegetarian women. Additionally, in these studies, the number of observations is
often restricted to 1–2 menstrual cycles. Furthermore, some studies lack of significance because they
considered underpowered and not randomized groups. Finally, others studies performed in larger
populations could be affected by peculiar lifestyles (such as abstention from drugs, alcohol, tobacco,
and caffeine-containing beverages) [293], thus making impossible to elucidate the specific role of the
vegetarian/vegan diet.
In some studies performed in female mammals, the impact of dietary proteins was associated
with changes in HPG axis regulation: in particular, a higher intake of proteins was shown to enhance
GnRH-induced LH release [300,301]. Conversely, in other studies, diets deficient in proteins delay
puberty in female ruminants but does not impair the synthesis and processing of LHRH in the brain
neurons and synthesis of LH in pituitary cells [302]. Furthermore, most studies done in female
ruminants showed that higher intake of proteins increases ovarian activity by non LH-mediated
pathways, but acting at a local level, through changes in insulin [303] or IGF system, by enhancing
the sensitivity of follicles toward FSH and regulating oocyte quality [304]. According to this data, we
demonstrated that a diet enriched in amino acids is able to partly counteract the block of estrous cycle
progression in mouse females subjected to 40% calorie restriction: this effect is mediated by changes
in IGF-1 levels that we showed to be dependent on the hepatic activity of estrogen receptor alpha
(ERα) [10].
Dietary intake of proteins may affect the circulating levels of P4, although different studies
led to opposite results and others showed no changes [305–307]. The discrepancy could be related
to the different protein-enriched diets adopted in these studies (different percentage of proteins or
different source of proteins). Another explanation for these conflicting responses could be ascribable
to the difference in the lactation status: high dietary proteins reduced plasma P4 concentrations in
lactating [305,306,308], but not in non-lactating female mammals [308–311].
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In women under physiological conditions, amino acids levels fluctuate during the menstrual
cycle and, in particular, decrease in the luteal phase [312–314]. It has been suggested that the decreased
plasma amino acid levels reflect an increased utilization and could be due to the raised levels of
P4 and E2 [312,315,316]. Although the dietary intake of proteins has not been evaluated during the
menstrual cycle progression, the decreased in plasma amino acid levels measured during the luteal
phase could be the consequence of the increased physiological demands of metabolic intermediates
for steroid synthesis by the corpus luteum as well as glycogenesis [317,318], protein synthesis and
secretion by the endometrium [319]. This fascinating suggestion might further explain the association
between the reduced fertility in women observed nowadays and the decrease in protein intake in the
industrialized societies compared to the nutritional environment for which our genetic constitution
was selected [200,320].
6.4. Food-Associated Endocrine Disrupting Chemicals and Female Fertility
Some naturally-occurring or industrial-derived food components can have adverse effects per
se and could interfere and impair the signaling pathways regulating the reproductive process. It
has been shown that very high doses of genistein, a phytoestrogen present in food in particular in
soy milk, could have adverse effects on female reproductive physiology [321] and on pregnancy
outcomes [322–324]. Similarly, endocrine disrupting chemicals (EDCs) present in food as additives or
contaminants [325] were proposed to be associated with altered reproductive functions both in males
and females [326–331].
Some substances, for their chemical structures, could accumulate in tissues and, once mobilized
under energetic imbalance, could exert their action in the whole organism. For example, it has been
reported that genistein might accumulate in placenta [332] or in body depots [333], where, once
mobilized during fasting, might reach the fetus through the maternal-fetal transfer [334–336].
In females, EDCs affect steroidogenesis by acting on the HPG axis [325,337–339], impair
ovarian development and function [340–347] and cause uterine and ovarian alterations such as
endometriosis [348–351], premature ovarian failure (POF) [352] and PCOS [353].
Although the mechanisms of action of ECDs are difficult to unravel given the complexity
of the endocrine system, ECDs were demonstrated to interfere with the ER or the androgen
receptor (AR) signaling resulting in synergistic or antagonistic outcomes [354]. Furthermore, ECDs
can modify hormones bioavailability by interfering with their synthesis, secretion, transport and
metabolism [355–361].
7. The Beneficial Effects of Mediterranean Diet for Women Health
The benefits of the Mediterranean-type diet [362,363] on health [364,365] include a significant
reduction of the incidence of metabolic [366–372], cardiovascular [373–378], neurodegenerative
diseases [379–382], and cancer [383–385]. In fertile age women, the adherence to the Mediterranean-type diet
seems to reduce the risk of weight gain and insulin resistance [386–391], thereby increasing the
chance of pregnancy, as suggested by a study showing a 40% increase in successful pregnancy among
couples undergoing IVF [392]. Furthermore, the adherence to Mediterranean-style dietary pattern
was inversely associated with the risk of developing obstetric complications associated with adverse
health outcomes for the mother and child, including hypertensive disorders of pregnancy (HDPs) [393],
preterm delivery [394], gestational diabetes mellitus [395,396], low intra-uterine size and low birth
weight [397]. For these evidences the Mediterranean diet has been suggested as a “preconception diet”
for couples undergoing in vitro fertilization treatment [392].
Although the studies that specifically evaluate the effects of the Mediterranean-type diet on
women fertility are scarce, different studies done on female experimental mammals suggested that
the increased intake of vegetable oils that are rich in linoleic acid, an n-6 fatty acid, which can only
be obtained by the diet, may improve the reproductive process. In fact, linoleic acid and others n-6
fatty acids, being precursors of the prostaglandins, might play an important role in the initiation of the
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menstrual cycle [398], growth, and development of pre antral follicles and ovulation [232,399], as like
in the maintenance of pregnancy by optimizing endometrial receptivity [229,400,401]. Some studies
showed that consuming n-6 PUFA instead of TFA was associated with a reduced risk of ovulatory
infertility [402].
On the other hand, other studies seem to disprove these indications reporting that the adherence
to Mediterranean diet was not associated with lower incidence of menstrual disturbances [233] or with
reduced risk of pregnancy loss [403,404].
8. Conclusions
Although different studies suggest that physical activity and a proper diet, in particular the
daily intake of different classes of nutrients, could significantly improve reproductive outcomes [4],
the identification of a fertility diet is still the “Holy Grail” in female infertility management. The
main causes rely on the lack of a full comprehension of the activity and mechanisms of action of
many nutrients, along with other variables such as lifestyle, physical activity, and genetic and cultural
backgrounds. Unfortunately, we are far from shedding a light on this area of research; first of all
because of the paucity of the studies present in the literature. Secondary, it is still difficult to recruit
and to persuade healthy volunteers to participate in longitudinal studies based on nutrition and
lifestyle interventions. Furthermore, the different protocols adopted during clinical tests often resulted
underpowered and not randomized, thus leading to conflicting results. The lack of longitudinal studies
focused on the reproductive outcome of diet that could, at the same time, evaluate the differences in
lifestyle, physical activity, genetic and cultural backgrounds is a main problem. Additionally, the lack
of a common protocol of analysis (the methods used, the parameters and the endpoints evaluated are
generally different among the different studies) makes it impossible to integrate the high heterogeneity
of data available and currently represent a main hindrance in leading to conclusive results.
Nevertheless, nutrition and lifestyle changes are still one of the most promising and invaluable
interventions in preserving human health and women fertility and represent the most captivating
challenge that we also have to take up today as Hippocrates, in the 4th century BC, suggested:
“If we could give every individual the right amount of nourishment and exercise, not too little
and not too much, we would have found the safest way to health”.
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